• Xenetic Biosciences posted a GAAP net loss of USD 929,695 for the quarter ended June 30, 2026, widening 35% year over year.
• Revenue rose 12% to USD 660,601, driven by higher royalty revenue tied to its Takeda sublicense in certain countries.
• Operating loss widened 34.1% to USD 971,690 as total operating costs and expenses climbed 24.2% to USD 1.63 million.
• R&D expense fell 15.9% to USD 552,013, while G&A jumped 64.2% to USD 1.08 million on higher legal costs tied to a strategic review.
• The board is running a formal strategic review that includes options such as an asset sale or reverse merger, while continuing to advance its systemic DNase program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xenetic Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001683168-26-006061), on August 06, 2026, and is solely responsible for the information contained therein.